Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction

Georg Griesinger*, Herman Tournaye, Nick Macklon, Felice Petraglia, Petra Arck, Christophe Blockeel, Peter van Amsterdam, Claire Pexman-Fieth, Bart Cjm Fauser

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review


The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.

Sider (fra-til)249-259
Antal sider11
TidsskriftReproductive BioMedicine Online
Udgave nummer2
StatusUdgivet - feb. 2019

Bibliografisk note

Copyright � 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.


Udforsk hvilke forskningsemner 'Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction' indeholder.